RecruitingNCT06526741
Renal
Thin Basement Membrane Nephropathy
Also known as benign familial hematuria, thin GBM disease, TBMN
Thin basement membrane nephropathy is characterised by persistent glomerular haematuria due to abnormal thinning of the glomerular basement membrane, most commonly caused by heterozygous mutations in COL4A3 or COL4A4, the same genes implica
ORPHA:93570 ↗Gene COL4A3Gene COL4A4Prevalence Approximately 1 in 100–200 (one of the most common hereditary renal conditions)Onset Any age; often detected in childhood or early adulthood
3
studies recruiting now
as of 7 Sept 2026
6
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
30 Jul 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT02378805
Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
RecruitingNCT06065852
National Registry of Rare Kidney Diseases
Showing the 3 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
Search all Thin Basement Membrane Nephropathy studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Thin Basement Membrane Nephropathy study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: European Alport Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Thin Basement Membrane Nephropathy
Thin basement membrane nephropathy is characterised by persistent glomerular haematuria due to abnormal thinning of the glomerular basement membrane, most commonly caused by heterozygous mutations in COL4A3 or COL4A4, the same genes implicated in Alport syndrome. Previously considered uniformly benign, it is now recognised that a subset of patients, particularly those with additional genetic risk factors, develop significant proteinuria and progressive renal failure. The condition overlaps genetically and clinically with autosomal recessive Alport syndrome, and careful monitoring is essential.
Common clinical features
Persistent microscopic haematuria (isolated, without casts)Episodic macroscopic haematuria following upper respiratory infectionsMild to moderate proteinuria (in progressive cases)Normal renal function in most patientsHypertension (in progressive cases)Family history of haematuria in first-degree relativesThin GBM on electron microscopy of renal biopsy
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Before you apply
Things trial teams commonly ask about for Thin Basement Membrane Nephropathy. Not eligibility rules; those are set by each study.
- Genetic testing for COL4A3/COL4A4 mutations is increasingly required to distinguish TBMN from Alport syndrome and to stratify disease progression risk; pursue full gene sequencing.
- Annual monitoring of proteinuria, eGFR, and blood pressure is recommended and provides the longitudinal data needed for trial eligibility assessment regarding rate of progression.
- Trials for COL4-related nephropathies may enrol both TBMN and Alport syndrome patients under a broader COL4A3/COL4A4 disease category; check for inclusive eligibility criteria.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).